GlassScriptPhysician profile
Chonyang Lu Albert
NPI 1194084202
$3,667.13
in general payments reported to CMS, 2019-2025
23 companies · $1,792 in 2025
The $1,792 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2023: $423 · 2024: $1,280 · 2025: $1,792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,098 · Education: $264 · Travel and Lodging: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,098.47 |
| Education | $264.03 |
| Travel and Lodging | $132.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,613.16 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip, Cardiomems |
| Abiomed | $786.10 | 2024-2025 | Impella |
| Eurofins Viracor, LLC | $416.72 | 2025 | |
| Daxor Corporation | $123.56 | 2023 | Bva-100 |
| Atricure, INC. | $83.64 | 2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Cvrx, INC. | $77.82 | 2024-2025 | Barostim Neo System |
| Takeda Pharmaceuticals U.S.A., INC. | $69.19 | 2024 | Livtencity |
| Teleflex LLC | $59.76 | 2025 | |
| One Lambda, INC. | $50.95 | 2025 | |
| Pfizer INC. | $50.78 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $48.46 | 2024-2025 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $36.88 | 2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $33.76 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $32.43 | 2024-2025 | Camzyos |
| Ancora Heart, INC. | $28.15 | 2024 | Accucinch |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $24.00 | 2025 | Sapien 3 Ultra Resilia |
| Analog Devices INC. | $23.20 | 2025 | Sensinel Cpm Wearable |
| Scpharmaceuticals INC. | $20.94 | 2024 | |
| Astellas Pharma US INC | $20.13 | 2025 | Cresemba |
| Daiichi Sankyo INC. | $19.00 | 2025 | Injectafer |
| Impulse Dynamics (USA) INC. | $18.03 | 2024 | Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.78 | 2025 | |
| Kestra Medical Technology Services, INC. | $13.69 | 2025 | Assure Wcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chonyang Albert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.